Social Rundown: Decades old submarine, Study helps pets live longer, Unhinged job landings
WICHITA FALLS (KFDX/KJTL) — Welcome back to the Social Rundown, where you can learn about the online trends happening globally and in Texoma, too!
Want to get the latest tea or news on what's trending on social media? Tune in daily!
A 108-year-old submarine that crashed and sank during an exercise training in 1917 was deemed lost, but was now found after deep-sea training off the coast of San Diego.
Through a research study and clinical trial, your pet may now have the opportunity to live a longer life. The Stay Study is in the final test before Company Loyal submits to the FDA for approval.
People on the job hunt are likely tweaking their resumes, cover letters, and networking strategies to make themselves more presentable, but others have gone to extreme lengths to land the job.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
7 minutes ago
- Time Business News
When to Choose Strattera Over Adderall
Attention-Deficit/Hyperactivity Disorder (ADHD) affects millions of people worldwide, leading to difficulties with focus, impulsivity, and hyperactivity. While stimulant medications like Adderall are often the first line of treatment, non-stimulant options such as Strattera (atomoxetine) can be a more appropriate choice in certain situations. Understanding when to choose strattera vs adderall involves evaluating factors such as the patient's medical history, potential side effects, risk of substance abuse, and overall treatment goals. When managing depression and anxiety, selecting the appropriate medication is crucial for effective treatment. Both medications in question are popular SSRIs that help balance serotonin levels in the brain, improving mood and emotional stability. In the middle of this discussion, Lexapro vs zoloft often arises as a common comparison due to their similar uses but distinct side effect profiles and dosing schedules. While some patients respond better to one, others may experience fewer adverse effects or more rapid relief with the alternative. Consulting a healthcare provider is essential to tailor the choice to individual needs and medical history. Strattera and Adderall are both approved by the FDA for treating ADHD but function in very different ways. Adderall is a stimulant composed of amphetamine salts that work by increasing the levels of dopamine and norepinephrine in the brain. This results in improved attention, reduced impulsivity, and greater overall concentration. On the other hand, Strattera is a selective norepinephrine reuptake inhibitor (NRI), which means it primarily boosts norepinephrine without significantly impacting dopamine levels. Unlike Adderall, Strattera is not a controlled substance and carries a much lower risk of abuse. One of the primary reasons to choose Strattera over Adderall is when there's a concern about substance misuse or a history of addiction. Adderall is a Schedule II controlled substance due to its high potential for abuse and dependency. For individuals with a history of substance use disorder, Adderall may pose a serious risk. Strattera, being non-stimulant and non-addictive, offers a safer alternative. It allows for effective ADHD management without the risk of reinforcing addictive behaviors, making it particularly useful in populations vulnerable to stimulant misuse. Many individuals with ADHD also suffer from comorbid mental health conditions like anxiety or depression. In such cases, Strattera may be a better option than Adderall. Stimulants like Adderall can exacerbate anxiety symptoms in some patients, leading to increased restlessness, jitteriness, or panic attacks. Strattera, on the other hand, has shown some efficacy in improving symptoms of anxiety and may also provide mild antidepressant effects due to its norepinephrine-enhancing properties. Choosing Strattera can help manage both ADHD and accompanying mood or anxiety disorders without worsening either condition. Adderall, especially the immediate-release version, has a relatively short duration of action, requiring multiple doses throughout the day. Even the extended-release versions may wear off by late afternoon or evening. In contrast, Strattera is taken once daily and offers 24-hour symptom coverage. This can be particularly advantageous for individuals who need consistent control over their ADHD symptoms throughout the day and into the evening. Students, working professionals, or parents managing multiple responsibilities might find this steady effect preferable to the peaks and troughs associated with stimulant medications. While stimulants are effective for many people, they also come with a host of potential side effects, including insomnia, appetite suppression, irritability, increased heart rate, and elevated blood pressure. For some individuals, these side effects can be intolerable or even dangerous, particularly if they have underlying cardiovascular issues. Strattera generally has a milder side effect profile and is not associated with the same degree of appetite suppression or cardiovascular stimulation. Although it has its own set of side effects, such as nausea or fatigue, these are often more manageable and tend to lessen over time. In some clinical scenarios, a non-stimulant medication like Strattera is the preferred first-line treatment. For example, in younger children (especially those under six years of age), stimulants may not be recommended due to potential side effects and lack of data on long-term safety. Pediatricians may opt for Strattera as a gentler initial approach. Additionally, parents who are concerned about the stigma or potential long-term effects of stimulant use may feel more comfortable starting their child on a non-stimulant option. Stimulants such as Adderall can interfere with sleep, especially if taken later in the day. Sleep disturbances are a common complaint among stimulant users and can contribute to irritability, mood swings, and worsening of ADHD symptoms. Strattera is less likely to cause sleep disruption and may even help improve sleep quality for some patients. For individuals who already struggle with insomnia or erratic sleep patterns, Strattera may be the better treatment choice. One of the key differences between Adderall and Strattera is how quickly they take effect. Adderall typically produces noticeable results within hours, making it ideal for patients seeking immediate symptom relief. Strattera, however, requires several days to weeks to build up in the system and reach full therapeutic effect. For patients and clinicians willing to adopt a slower, more gradual treatment approach, this delayed onset can be worthwhile, especially given Strattera's longer-term stability and lower side effect profile. Because Adderall is a controlled substance, it comes with regulatory burdens such as limited refills, stricter prescribing rules, and potential stigma. Some patients or caregivers may prefer a treatment that does not involve these complications. Strattera, being non-controlled, can be prescribed more freely and refilled more easily. This can improve medication adherence and reduce the hassle associated with frequent doctor visits or pharmacy restrictions. In some cases, clinicians may not be completely certain whether a patient's symptoms are primarily due to ADHD or another condition such as anxiety, depression, or trauma-related disorders. Since stimulants can exacerbate certain psychiatric symptoms or produce euphoria, starting with a non-stimulant like Strattera can be a safer way to assess a patient's response without clouding the diagnostic picture. If symptoms improve with Strattera, it may confirm that norepinephrine imbalance plays a role in the condition, guiding future treatment decisions. Choosing between Strattera and Adderall requires a personalized approach that considers the individual's medical history, lifestyle, comorbid conditions, and treatment preferences. While Adderall remains highly effective for many, Strattera presents a viable and often safer alternative for those with substance abuse risks, anxiety, sleep disturbances, or cardiovascular concerns. It is also a strong option for patients seeking all-day symptom coverage or those who prefer to avoid controlled substances. Consulting with a knowledgeable healthcare provider is crucial in determining which medication best aligns with the patient's needs and long-term goals. TIME BUSINESS NEWS
Yahoo
41 minutes ago
- Yahoo
Does drinking coffee daily make women healthier? Twin doctors explain
(NewsNation) — Doctors Idries and Jamil Abdur-Rahman debunk medical myths and answer medical questions on 'Morning in America,' including the benefits of coffee for women, whether plant-based burgers are healthier than beef patties and what determines pregnancy symptoms. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market
Explore the booming PTSD therapeutics market, projected to grow from $1.2 billion in 2024 to $5.4 billion by 2034 at a 15.8% CAGR. Key drivers include new pipeline products and psychedelic therapeutics. Discover market insights, competitor analysis, and strategic opportunities in the 7MM market. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast" report has been added to report covers the 7MM and provides an Excel-based forecast model for the Post-Traumatic Stress Disorder market through psychotherapy is widely considered to be the first line of therapeutic intervention for PTSD patients, with pharmacotherapy often used as an adjunct to psychotherapy. Only two drugs, both SSRIs, have been approved by the FDA for the treatment of PTSD: Zoloft (sertraline) and Paxil (paroxetine). The central issue with pharmacotherapy in PTSD is a lack of efficacy of available treatments. The PTSD market across the 7MM was valued at $1.2 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 15.8%, reaching $5.4 billion by 2034. A key driver of growth will be the launch of eight late-stage pipeline products, including the first psychedelic therapeutics for Scope Overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, symptoms, diagnosis, and disease management. Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PTSD market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD. The most promising candidates in late-stage development are profiled. Analysis of the current and future market competition in the 7MM PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the 7MM PTSD therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the PTSD therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Company Coverage: GSK Eli Lilly and Co Otsuka Pharmaceutical Co Ltd Pfizer Seelos Therapeutics Ananda Scientific Lykos Therapeutics Idorsia Pharmaceutical Compass Pathways Transcend Therapeutics Neuphoria Therapeutics Key Topics Covered: 1. Preface2. Executive Summary3. Disease Overview3.1. Overview of PTSD3.2. Pathophysiology of PTSD3.3. Classification of PTSD3.4. PTSD SWOT Analysis4. Epidemiology4.1. 12-Month Total Prevalent Cases of PTSD, Men and Women, Ages ? 18 Years, 2024?344.2. Age-Specific 12-Month Total Prevalent Cases of PTSD, Men and Women, 20244.3. Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ?18 Years, 20244.4. 12-Month Total Prevalent Cases of PTSD by Disease Status, Men and Women, Ages ?18 Years, 20244.5. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD4.6. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Disease Status4.7. Sources Used to Forecast the 12Month Total Prevalent Cases of PTSD by Military Status4.8. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD4.9. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD by Disease Status5. Current Treatment Options5.1. Treatment Paradigm5.2. Current Treatment Options5.3. Product Profile: Pfizer's Zoloft/Besitran/Lustral (sertraline)5.4. Product Profile: GSK's Paxil/Deroxat/Seroxat/Aropax (paroxetine)5.5. Product Profile: Eli Lilly's Prozac (fluoxetine)5.6. Product Profile: Pfizer's Effexor XR/Effexor/Effexor XL/Vandral (venlafaxine)5.7. Product Profile: Pfizer's Minipress/Hypovase (prazosin)5.8. Patient Flow: PTSD in 2024 Across 7MM6. Unmet Needs and Opportunities6.1. Unmet Needs in PTSD6.2. New Therapeutic Options with Improved Efficacy6.3. Increase Access to Psychotherapy6.4. Treatment Options with Improved Side-Effect Profiles6.5. More consistent diagnostic and treatment guidelines7. R&D Strategies7.1. Trends in Clinical Trial Design in PTSD7.2. Regulatory Challenges for Psychedelic Treatments7.3. Timeline of Regulatory Challenges for Lykos Therapeutics7.4. Trends in Deal-Making in PTSD8. Pipeline Assessment8.1. PTSD Pipeline Overview8.2. Late-Stage Pipeline Agents for PTSD8.3. Product Profile: Otsuka Pharmaceutical's Rexulti (brexpiprazole)8.4. Product Profile: Neuphoria Therapeutics' BNC-2108.5. Product Profile: Idorsia Pharmaceutical's Quviviq (daridorexant)8.6. Product Profile: Ananda Scientific's Nantheia ATL5 (cannabidiol)8.7. Product Profile: Transcend Therapeutics' TSND-201 (methylone)8.8. Product Profile: Lykos Therapeutics' midomafetamine hydrochloride8.9. Product Profile: Seelos Therapeutics' Ereska (ketamine hydrochloride)8.10. Product Profile: Compass Pathways' COMP360 (psilocybin)8.11. PTSD: Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. PTSD Market Forecast9.2. Market Drivers and BarriersFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
